ropinirole prolonged release

**Ropinirole prolonged release** is a once-daily, 24-hour extended-release formulation of ropinirole, a non-ergot dopamine D2/D3 receptor agonist. It is indicated as monotherapy or as adjunctive therapy to levodopa for the treatment of Parkinson’s disease, improving both motor and non-motor symptoms. This formulation is designed as a three-layer tablet, allowing gradual drug delivery and maintaining steadier plasma concentrations over 24 hours. Key advantages over immediate-release include improved patient compliance, simpler dosing, and reduced motor fluctuations. Ropinirole prolonged release is well-tolerated with a safety profile similar to other non-ergot dopamine agonists, with common side effects including nausea, somnolence, dizziness, and orthostatic hypotension. Serious side effects may include hallucinations, impulse control disorders, and sudden sleep episodes[1][7].

Brand names

Requip XL

Other names

ropinirole extended-releaseropinirole modified release